Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
Black Diamond Therapeutics disclosed its financial results for the six months ended June 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes consolidated balance sheet data, statements of operations with revenue and net loss figures, and cash position disclosures. This is a standard earnings release announcement for a clinical-stage company reporting quarterly/semi-annual financial results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-05
Item 2.02
AbCellera issued a press release on August 5, 2026 announcing Q2 2026 financial results, including revenue of $4.1 million, net loss of $55.4 million, and cash balances of over $565 million, along with business updates on clinical programs and new collaborations with Jazz and Vertex.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Granite Point Mortgage Trust Inc. issued a press release on August 5, 2026, announcing its financial results for the fiscal quarter ended June 30, 2026, including GAAP net loss of $(62.0) million per share, distributable earnings loss, balance sheet data, and portfolio metrics. This is a standard quarterly earnings disclosure filed under Item 2.02 with exhibits 99.1 and 99.2 attached, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Ecovyst issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 sales of $250.0 million (up 42% YoY), net income of $10.7 million, Adjusted EBITDA of $53.1 million (up 27% YoY), and raising full-year 2026 guidance for Adjusted EBITDA to $195–$207 million. This is a standard quarterly earnings release with material financial results and forward guidance, filed under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-05
EX-99.1
This is a press release announcing GlobalFoundries' second quarter 2026 financial results, including revenue of $1.786 billion, gross margin of 28.3%, net income of $167 million, and diluted EPS of $0.30. The document presents consolidated statements of operations, balance sheet, and cash flows for the quarter ended June 30, 2026, along with forward guidance for Q3 2026. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Hamilton Beach Brands issued a press release on August 5, 2026 announcing unaudited financial results for Q2 2026 ended June 30, 2026. The disclosure includes revenue of $142.6 million (up 11.6%), gross margin of 54.3%, operating profit of $43.2 million, and diluted EPS of $2.49, along with full consolidated financial statements and updated 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
Liberty Latin America issued a press release on August 5, 2026 announcing its operating and financial results for Q2 2026 (quarter ended June 30, 2026). The filing explicitly states the press release is furnished under Item 2.02 "Results of Operations and Financial Condition," and the exhibit contains comprehensive quarterly financial and operating highlights including revenue, operating income, Adjusted OIBDA, cash flow, and segment performance metrics. This is a standard quarterly earnings disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
Adicet Bio announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $21.4 million ($1.99 per share), R&D and G&A expenses, cash position of $118.2 million, and balance sheet information. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Arcus Biosciences issued a press release on August 5, 2026 announcing financial results for the six months ended June 30, 2026, disclosing Q2 2026 revenues ($41 million), R&D expenses ($113 million), G&A expenses ($24 million), net loss ($91 million), and cash position ($775 million). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the full press release furnished as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-05
Item 3.03
Twin Vee's purported reincorporation from Delaware to Nevada in April 2026 was invalid due to insufficient shareholder approval under Delaware law, and the reverse stock split executed under Nevada law was therefore not valid under Delaware law. The company is seeking stockholder ratification of the 1-for-37 reverse stock split under Delaware law and has filed corrective documentation to address the defective corporate act.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-05
Item 7.01
Splash Beverage Group announced entry into a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil® through FDA veterinary regulatory pathways. This is a material operational and strategic partnership involving a defined development program with milestone-based funding, regulatory execution, and commercialization rights retention. While it involves a partnership and capital commitment, it does not fit the specific categories of M&A activity (no acquisition/merger/change of control), debt issuance, or other named financial events—it is a strategic operational collaboration that would affect investor assessment of the company's business direction and capital allocation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-05
EX-99.1
This press release announces the official launch of the YeeZo University AI Content Training Program, a strategic university-to-industry initiative designed to train students in AI-generated content production. The announcement describes a material operational and strategic business development—a new product/service offering and market entry strategy—that does not fit a specific named category. The company explicitly states this "marks the official debut of RYET's broader YeeZo education-to-industry strategy" and outlines a four-pillar strategic framework. While forward-looking and contingent on university partnerships, the launch of a major new business line targeting a large addressable market (602 million generative-AI users in China, RMB 1.29 trillion online-audiovisual market) would affect a reasonable investor's assessment of the company's strategic direction and growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-05
Item 8.01
VisionWave announced execution of a binding term sheet on August 2, 2026, to acquire a controlling interest (at least 51%) in D-Fence Electronic Fencing Systems Ltd., an Israeli AI-powered perimeter security company, with an implied valuation of approximately $5 million for the initial stake and $20 million for the remaining 49% equity option. This material acquisition transaction requires stockholder approval and represents a significant strategic expansion of VisionWave's defense technology portfolio.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
This is a clear earnings release for the second quarter and first six months of 2026. The press release discloses consolidated net income of $600K ($0.01 EPS) for Q2 2026 versus a net loss of $2.5M ($0.06 loss per share) in Q2 2025, and year-to-date EPS of $2.33 versus $2.11 in the prior year. The company also provides 2026 full-year EPS guidance (upper half of $2.95–$3.15 range) and reaffirms long-term growth targets. This is a material disclosure affecting investor assessment of financial performance and forward guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
This is a clear earnings release disclosing Elanco's second quarter 2026 financial results, including revenue of $1,368 million (10% YoY growth), adjusted net income of $174 million, and adjusted EPS of $0.34. The filing also provides updated full-year 2026 guidance with raised revenue, EBITDA, and EPS targets. The press release is dated August 5, 2026, and is attached as Exhibit 99.1 to Item 2.02, which is the standard Item for results of operations disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operation and Financial Condition). The release discloses second quarter revenues of $658.7 million (up 2% YoY), adjusted EBITDA of $145.9 million (up 5% YoY), and adjusted diluted EPS of $1.13 (up 5% YoY), along with detailed segment performance and cash flow metrics. The earnings release is attached as Exhibit 99.1 and constitutes the primary disclosure required by Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-05
Item 2.02
The filing discloses Walt Disney Co's quarterly financial results for Q3 fiscal 2026 (quarter ended June 27, 2026) via an earnings release furnished as Exhibit 99.1. The release presents summarized financial results including revenues ($25.2 billion, up 7%), income before income taxes ($3.6 billion, up 14%), total segment operating income ($5.6 billion, up 21%), and adjusted EPS ($2.06, up 28%), along with segment-level performance and forward guidance for fiscal 2026 and 2027. This is a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Blue Owl Technology Finance Corp. issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes GAAP net investment income per share of $0.30, adjusted NII per share of $0.30, NAV per share of $16.48, portfolio composition, investment activity, and detailed results of operations. This is a standard quarterly earnings release for a BDC, material to investors assessing the company's financial performance and position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-05
Item 2.02
AppLovin issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing revenue of $1,924 million (53% YoY growth), net income of $1,267 million (55% YoY growth), and Adjusted EBITDA of $1,614 million (58% YoY growth), along with Q3 2026 guidance. This is a standard quarterly earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-05
Item 1.01
ClearOne entered into a warrant cancellation agreement on August 4, 2026, in connection with the Agreement and Plan of Merger dated July 1, 2026, involving ClearOne, CLRO Merger Sub, Cortigent, and Vivani Medical. The warrant cancellation is a material ancillary transaction tied to the underlying merger activity.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-08-05
Item 5.02
ClearOne established a new employment agreement with Simon Brewer (CFO) effective upon completion of the Cortigent acquisition, providing a $300,000 annual base salary, discretionary performance bonus eligibility, 200,000 stock options with 25% annual vesting, six months' severance plus COBRA, and non-compete/non-disparagement covenants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-08-05
Item 5.07
ClearOne stockholders approved by written consent on August 3, 2026, the issuance of 12,500,000 shares (representing more than 20% of outstanding stock and triggering a change of control under Nasdaq rules) and the adoption of the 2026 Omnibus Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-05
Item 5.07
This is a clear disclosure of shareholder voting results from a special meeting held on August 5, 2026. The filing reports the vote tallies for two proposals: approval of Delaware domestication and approval of an adjournment proposal. The Delaware domestication proposal is material as it involves a change in the company's domicile jurisdiction, which affects corporate governance and legal structure. Item 5.07 is the designated item for shareholder vote results, and the prose explicitly states these are results from the Special Meeting voted upon by shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Envista issued a press release on August 5, 2026 announcing Q2 2026 financial results for the quarter ended July 3, 2026, with Q2 sales of $731 million (5.0% core growth), adjusted diluted EPS of $0.41 (+58% YoY), and adjusted EBITDA of $108 million (+28% YoY), along with raised full-year 2026 guidance for core sales growth, adjusted EBITDA, and adjusted EPS.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-05
Item 8.01
The Board declared an increase in the regular quarterly cash dividend from an implied $0.45 per share to $0.47 per share (a 4.4% increase), payable August 28, 2026 to stockholders of record as of August 21, 2026. This is a clear dividend distribution event with a material increase that signals management confidence and affects shareholder returns.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
Mirum Pharmaceuticals issued a press release on August 5, 2026, disclosing Q2 2026 financial results, including net product sales of $176.2 million and raising full-year guidance to $680–$700 million. The filing explicitly states this is a disclosure of "Results of Operations and Financial Condition" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard earnings release for a quarterly period.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-05
Item 7.01
The filing discloses a Stock Purchase Agreement entered into on May 20, 2026, whereby Kontoor Brands has agreed to sell its H.D. Lee Company subsidiary to ABG-Storm LLC (an Authentic Brands Group affiliate). The company commenced a sale process in Q1 2026 and determined the Lee business met held-for-sale criteria, reporting it as discontinued operations. This represents a material disposition of a business segment that will have a major effect on the company's operations and financial results, as explicitly stated in the disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-05
Item 2.02
Pennant Group issued a press release on August 5, 2026 reporting Q2 2026 financial results, including GAAP diluted EPS of $0.25, adjusted diluted EPS of $0.36, total revenue of $298.0 million (up 35.8% YoY), and net income of $9.1 million (up 28.2% YoY), along with updated 2026 guidance and detailed segment performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
XPEL disclosed consolidated financial results for Q2 and six months ended June 30, 2026 via press release attached as Exhibit 99.1. The disclosure reports record revenue of $143.1 million (14.7% growth), net income of $18.0 million (10.7% growth), and EPS of $0.65, along with detailed financial statements and forward guidance for Q3 2026. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Dynatrace announced first quarter fiscal 2027 financial results (ended June 30, 2026) with ARR of $2,136 million (17% growth), total revenue of $555 million (16% growth), and GAAP net income per share of $0.12, along with detailed financial highlights and forward guidance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 94%
filed 2026-08-05
Item 5.02
James Benson, Executive Vice President and Chief Financial Officer, notified the Company on July 31, 2026 that he will resign from his position by March 31, 2027 in connection with his planned retirement. The company has initiated a CFO search, and Benson will oversee the transition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Arcutis reported Q2 2026 financial results with product revenues of $129.9 million (up 59% year-over-year) and net income of $15.0 million ($0.11 per share). The company raised its full-year 2026 guidance to $525–$540 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-05
Item 5.02
Robert Lisicki was appointed as interim executive vice president and interim chief commercial officer effective August 21, 2026, following L. Todd Edwards' resignation. Lisicki's compensation includes a base salary of $555,000, 50% target bonus, 145,000 option grant, and 55,000 RSUs, with severance arrangements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-05
Item 2.02
Root, Inc. announced its financial results for the quarter ended June 30, 2026, disclosing net income of $25 million (up 15% YoY), revenue of $389 million (up 2% YoY), adjusted EBITDA of $44 million (up 16% YoY), policies in force of 484 thousand (up 6% YoY), and a net combined ratio of 92.1%.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
This is a clear earnings release disclosing Xperi's second quarter 2026 financial results for the period ended June 30, 2026. The Item 2.02 section explicitly states the company "announced its financial results for the second quarter ended June 30, 2026" with a press release furnished as Exhibit 99.1. The press release contains GAAP and non-GAAP financial highlights, revenue growth metrics (54% advertising revenue growth, 70% user growth), and updated guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
This is a quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including R&D expenses ($14.0M), G&A expenses ($5.0M), net loss ($17.3M or $0.27 per share), and cash position ($182.7M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements. Material to investors as it reports the company's financial condition and operational performance for the period.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
DoorDash issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing strong growth across key metrics including Total Orders (970 million, +27% Y/Y), Marketplace GOV ($33.1 billion, +36% Y/Y), Revenue ($4.5 billion, +36% Y/Y), GAAP net income ($200 million), and Adjusted EBITDA ($914 million, +40% Y/Y), along with forward guidance for Q3 2026 and full-year 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
ZoomInfo issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing GAAP revenue of $310.4 million (1.2% YoY growth), a GAAP operating loss of $622.0 million (including a $650.5 million goodwill impairment), adjusted operating income of $110.0 million, and unlevered free cash flow of $107.3 million. The filing also includes forward guidance for Q3 2026 and full-year 2026. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Carlsmed issued a press release on August 5, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $18.9 million (57% YoY growth), gross margin expansion of 340 basis points, and raising full-year 2026 revenue guidance to $74–$78 million. The filing includes condensed statements of operations, balance sheets, and reconciliation tables, all hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-05
Item 2.02
Chime issued a press release on August 5, 2026 disclosing Q2 2026 financial results, including revenue of $670 million (up 27% YoY), net income of $28 million (second consecutive quarter of GAAP profitability), and raised full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-08-05
Item 2.05
Chime announced a committed reorganization plan involving a 10% workforce reduction, with estimated restructuring charges of $16–$20 million in net cash costs and a $6–$9 million impact to net income in Q3 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-05
Item 5.02
Matthew Newcomb resigned as Chief Financial Officer effective August 7, 2026. Mark Troughton was appointed as interim CFO, and Newcomb received a transition agreement and severance terms.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
This is a clear earnings release disclosing Clover Health's second quarter 2026 financial results, including GAAP Net Income of $28 million, Medicare Advantage membership of 157,309 (up 48% YoY), total revenues of $743 million (up 56% YoY), and improved full-year 2026 guidance across all metrics. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Royalty Pharma issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Portfolio Receipts of $773 million (6% growth), Royalty Receipts of $768 million (14% growth), and raising full-year 2026 guidance for Portfolio Receipts to $3,400–$3,500 million. This is a standard quarterly earnings release with detailed financial metrics, portfolio performance, and forward guidance, furnished as Exhibit 99.1 per Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
System1 issued a press release on August 5, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), disclosing revenue of $30.2 million, GAAP net loss of $15.3 million, and adjusted EBITDA of $1.9 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures on Form 8-K.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-05
Item 8.01
The Board of Directors declared a quarterly cash dividend of $0.14 per share of common stock, payable on September 3, 2026. This is a routine but material capital allocation decision that affects shareholder returns and is disclosed via press release. Dividend declarations are standard material events for public companies with established dividend policies.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
GoodRx disclosed its financial results for Q2 2026 (three and six months ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes revenue of $200.4 million, net income of $8.5 million, adjusted EBITDA of $63.7 million, and raised full-year 2026 guidance for both revenue ($790–$805 million) and adjusted EBITDA ($240–$250 million). This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-05
Item 5.02
The filing discloses both the departure of CFO Christopher McGinnis (effective August 5, 2026) and the appointment of Justin Fengler as Chief Financial Officer & Treasurer (effective August 6, 2026). While both events occur, the principal disclosed action centers on Fengler's appointment to the CFO role, which includes material compensatory arrangements ($600K RSU, $600K PSU, and $100K cash payment). The appointment of a new CFO is material to investors assessing financial leadership continuity and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-05
Item 2.02
Texas Pacific Land Corp disclosed financial results for Q2 2026 and the six-month period ended June 30, 2026, reporting record consolidated net income of $153.9 million ($2.23 per diluted share) for Q2 and $296.8 million for the six-month period, along with record revenues of $246.1 million and $482.9 million respectively, and record free cash flow of $155.5 million. The earnings announcement was communicated through an updated investor presentation and detailed press release with consolidated financial statements and operational highlights.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-05
Item 2.02
Pattern Group Inc. issued a press release on August 5, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing record revenues of $877 million (47% YoY growth), record NRR of 129%, net income of $27 million, and adjusted EBITDA of $54 million. The filing explicitly states the press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements (income statement, cash flows, balance sheet) and forward guidance for Q3 and full-year 2026. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →